# Fate Therapeutics
 (stock symbol: FATE) Logo in transparent PNG and SVG formats

## Fate Therapeutics
 Logo large

### Fate Therapeutics
 Logo large Download PNG (53.96 KB)

![Fate Therapeutics
 Logo large Download PNG (53.96 KB)](/img/orig/FATE_BIG-0bc97a49.png)

### Fate Therapeutics
 Logo large Download SVG (5.32 KB)

![Fate Therapeutics
 Logo large Download SVG (5.32 KB)](/img/orig/FATE_BIG-ec1e34df.svg)

## Fate Therapeutics
 Logo icon format

### Fate Therapeutics
 Logo icon format Download PNG (45.16 KB)

![Fate Therapeutics
 Logo icon format Download PNG (45.16 KB)](/img/orig/FATE-4cf234e2.png)

### Fate Therapeutics
 Logo icon format Download SVG (1.01 KB)

![Fate Therapeutics
 Logo icon format Download SVG (1.01 KB)](/img/orig/FATE-b3848075.svg)

## Fate Therapeutics
 Logo large for dark backgrounds

### Fate Therapeutics
 Logo large for dark backgrounds Download PNG (52.94 KB)

![Fate Therapeutics
 Logo large for dark backgrounds Download PNG (52.94 KB)](/img/orig/FATE_BIG.D-9495afe4.png)

### Fate Therapeutics
 Logo large for dark backgrounds Download SVG (5.32 KB)

![Fate Therapeutics
 Logo large for dark backgrounds Download SVG (5.32 KB)](/img/orig/FATE_BIG.D-c3ec1231.svg)

## About Fate Therapeutics


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

1. Website domain: fatetherapeutics.com
2. Employees: 542
3. Marketcap: $0.59 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
